Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₪7.00, the stock trades at a trailing P/E ratio of 6.2x. Average forward P/E is 18x in the Biotechs industry in Asia. Total returns to shareholders of 73% over the past three years. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₪6.17, the stock trades at a trailing P/E ratio of 6.1x. Average forward P/E is 18x in the Biotechs industry in Asia. Total returns to shareholders of 33% over the past three years. Reported Earnings • May 19
First quarter 2026 earnings released: US$0.081 loss per share (vs US$0.078 loss in 1Q 2025) First quarter 2026 results: US$0.081 loss per share (further deteriorated from US$0.078 loss in 1Q 2025). Revenue: US$2.18m (down 4.7% from 1Q 2025). Net loss: US$7.67m (loss widened 6.8% from 1Q 2025). Revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Asia are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Announcement • May 04
Compugen Ltd. to Report Q1, 2026 Results on May 18, 2026 Compugen Ltd. announced that they will report Q1, 2026 results Pre-Market on May 18, 2026 Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₪8.56, the stock trades at a trailing P/E ratio of 7.4x. Average forward P/E is 20x in the Biotechs industry in Asia. Total returns to shareholders of 271% over the past three years. Reported Earnings • Mar 04
Full year 2025 earnings released: EPS: US$0.38 (vs US$0.16 loss in FY 2024) Full year 2025 results: EPS: US$0.38 (up from US$0.16 loss in FY 2024). Revenue: US$72.8m (up 161% from FY 2024). Net income: US$35.3m (up US$49.6m from FY 2024). Profit margin: 49% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. New Risk • Mar 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). Announcement • Feb 17
Compugen Ltd. to Report Q4, 2025 Results on Mar 02, 2026 Compugen Ltd. announced that they will report Q4, 2025 results Pre-Market on Mar 02, 2026 Announcement • Feb 12
Compugen Ltd. Appoints Michele Holcomb to Its Board of Directors, Effective February 11, 2026 Compugen Ltd. announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. Dr. Holcomb is a strategic leader with more than 30 years of healthcare experience across biotech, pharmaceuticals, and healthcare services industries. She serves on both public and private boards, and has been a scientist, consultant, and executive, driving change through innovation and optimization at key interfaces. In her previous role as EVP, Chief Strategy and Business Development Officer at Cardinal Health, Dr. Holcomb leveraged an enterprise perspective and knowledge of the evolving healthcare landscape to define strategies, optimize the portfolio, and identify growth and innovation opportunities. She also led the execution and integration of investments, acquisitions, and partnerships. Prior to Cardinal Health, Dr. Holcomb was the Chief Operating Officer of Global R&D and SVP of Strategy, Portfolio, Search and Partnerships at Teva Pharmaceuticals. At Teva, her responsibilities included identifying and evaluating potential pipeline assets to license or acquire, project management of the internal pipeline, alliance management of external partnerships and overall pipeline portfolio management. She also spent 15 years at McKinsey & Company and was a Partner of the Global Pharmaceutical Practice and one of the founders of the firm's work in biotech. Dr. Holcomb is a member of the Board of Directors of PureTech Health plc where she is also a member of the Audit Committee and the Transaction Committee. She is a member of the Board of Directors of Kimball Electronics Inc., where she also chairs the Nominating and ESG (NESG) Committee. She also serves as a Board Director for Controlant hf (private). Dr. Holcomb is a member of the editorial advisory board of Pharmaceutical Executive and has lectured on healthcare strategy at Kellogg (Northwestern), Columbia, and Fuqua (Duke) business schools. Dr. Holcomb received a BS in chemistry from Stanford University and a PhD in chemistry from the University of California, Berkeley, and previously worked as an R&D chemist at Ciba-Geigy and Syntex Pharmaceuticals. Reported Earnings • Nov 11
Third quarter 2025 earnings released: US$0.075 loss per share (vs US$0.014 profit in 3Q 2024) Third quarter 2025 results: US$0.075 loss per share (down from US$0.014 profit in 3Q 2024). Net loss: US$6.98m (down US$8.26m from profit in 3Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Oct 27
Compugen Ltd. to Report Q3, 2025 Results on Nov 10, 2025 Compugen Ltd. announced that they will report Q3, 2025 results Pre-Market on Nov 10, 2025 Announcement • Oct 14
Compugen Ltd. to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Compugen Ltd. announced that pooled analysis of previously presented data, supporting the anti-tumor activity and safety profile of COM701 in heavily pre-treated patients with platinum resistant ovarian cancer (PROC), has been published as an abstract released by the European Society of Medical Oncology (ESMO). The abstract focuses on a pooled analysis of 60 evaluable patients with platinum resistant ovarian cancer from prior COM701 Phase 1 clinical trials. The analysis characterizes the outcomes of patients who derived clinical benefit including progression free survival data. An additional year of follow-up will be included in the poster. Based on the anticipated enrollment rate, the Company currently estimates interim analysis results at year end 2026. New Risk • Oct 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Share price has been volatile over the past 3 months (6.5% average weekly change). New Risk • Aug 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Aug 09
Second quarter 2025 earnings released: US$0.079 loss per share (vs US$0.024 loss in 2Q 2024) Second quarter 2025 results: US$0.079 loss per share (further deteriorated from US$0.024 loss in 2Q 2024). Revenue: US$1.26m (down 81% from 2Q 2024). Net loss: US$7.34m (loss widened 246% from 2Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Aug 07
Compugen Ltd., Annual General Meeting, Sep 16, 2025 Compugen Ltd., Annual General Meeting, Sep 16, 2025. Location: co. offices, Israel Announcement • Jul 23
Compugen Ltd. to Report Q2, 2025 Results on Aug 06, 2025 Compugen Ltd. announced that they will report Q2, 2025 results Pre-Market on Aug 06, 2025 Announcement • Jul 21
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer Compugen Ltd. announced that the first patient was dosed in the global randomized sub-trial 1 of adaptive platform trial, MAIA-ovarian (which stands for MAintenance Immunotherapy with an Anti-PVRIG antibody), evaluating maintenance therapy with single agent COM701, a potential first-in-class anti-PVRIG antibody in patients with relapsed platinum sensitive ovarian cancer. MAIA-ovarian is a global adaptive platform trial to evaluate the safety and efficacy of COM701 as maintenance monotherapy or combination therapy in patients with relapsed platinum sensitive ovarian cancer. The purpose of sub-trial 1 is to assess if COM701 delays the progression of ovarian cancer in patients with relapsed platinum sensitive ovarian cancer and further assess its safety profile in this disease setting. The adaptive-platform design enables additional sub-trials. Sub-trial 1 is a double-blind, randomized placebo-controlled trial in which 60 patients will be randomized in a 2:1 ratio to COM701 or placebo. Subsequent sub-trials may evaluate COM701 in combination with other anticancer drugs. For more information about this trial, visit clinicaltrials.gov, NCT06888921. Reported Earnings • May 19
First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.081 loss in 1Q 2024) First quarter 2025 results: US$0.078 loss per share (improved from US$0.081 loss in 1Q 2024). Revenue: US$2.28m (down 11% from 1Q 2024). Net loss: US$7.18m (loss narrowed 1.2% from 1Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • May 05
Compugen Ltd. to Report Q1, 2025 Results on May 19, 2025 Compugen Ltd. announced that they will report Q1, 2025 results Pre-Market on May 19, 2025 Buy Or Sell Opportunity • Apr 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 37% to ₪5.19. The fair value is estimated to be ₪6.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 81% over the last 3 years. Earnings per share has grown by 44%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are forecast to decline by 22% per annum over the same time period. Buy Or Sell Opportunity • Mar 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.4% to ₪5.53. The fair value is estimated to be ₪7.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 81% over the last 3 years. Earnings per share has grown by 44%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are forecast to decline by 22% per annum over the same time period. New Risk • Mar 05
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$14m Forecast net loss in 3 years: US$8.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings are forecast to decline by an average of 22% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$8.1m net loss in 3 years). Reported Earnings • Mar 05
Full year 2024 earnings released: US$0.16 loss per share (vs US$0.21 loss in FY 2023) Full year 2024 results: US$0.16 loss per share (improved from US$0.21 loss in FY 2023). Revenue: US$27.9m (down 17% from FY 2023). Net loss: US$14.2m (loss narrowed 24% from FY 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Feb 26
Compugen Ltd. Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™? with Ultima Genomics' Single Cell Genomics Sequencing Technology Compugen Ltd. announced results generated in a joint research collaboration, combining Compugen's AI/ML powered predictive computational discovery platform, Unigen, with high throughput single cell sequencing on Ultima's UG 100 to uncover new insights on gene structure for immuno-oncology. Some of the findings were presented at the AGBT conference. Compugen plans to further harness Ultima's technology to develop its proprietary single cell atlases for accelerated discovery of new immunotherapies. Key Findings: Comparative analysis using tumor samples from cancer patients, found high consistency in single-cell expression levels across Ultima Genomics' UG 100 and Illumina's Novaseq 6000 sequencing platforms. Gene structure information identified in this approach is contributing to the predictive models of Unigen. The outcomes from Compugen's preclinical and clinical trials enrich the proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. Announcement • Feb 18
Compugen Ltd. to Report Q4, 2024 Results on Mar 04, 2025 Compugen Ltd. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025 New Risk • Feb 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings are forecast to decline by an average of 43% per year for the foreseeable future. Announcement • Jan 08
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors Compugen Ltd. announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial . This Phase 1 multi-center dose escalation and dose expansion trial will evaluate the safety, tolerability, and pharmacokinetics of COM503 as monotherapy and in combination with Gilead's anti-PD1, zimberelimab in patients with advanced solid tumors. The trial was initiated in the fourth quarter of 2024 as planned. The primary objectives of this trial are to assess the safety and tolerability of COM503 as a monotherapy and in combination with zimberelimab in patients with advanced solid tumors and to identify the maximum tolerated dose /maximum administered dose and/or the recommended dose of COM503 as monotherapy and in combination with zimberelimab. For more information about the Phase 1 clinical trial, visit clinicaltrials.gov, NCT06759649. Announcement • Nov 27
Compugen Ltd. Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies Compugen Ltd. announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company’s potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer. Breakeven Date Change • Nov 13
Forecast to breakeven in 2024 The 2 analysts covering Compugen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$3.15m in 2024. Announcement • Nov 05
Compugen Ltd. to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 Compugen Ltd. announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program, Massachusetts General Hospital, Boston, MA, and an investigator in this study, as a poster presentation at the 39 Annual Meeting of SITC, taking place between November 8-10, 2024, in Houston, Texas. The data from this study along with data Compugen previously presented, demonstrate that COM701 is active, has a favorable safety profile, and is a differentiated immune checkpoint inhibitor. COM701 in combination with COM902 (Fc reduced anti-TIGIT) and pembrolizum AB (anti-PD-1) resulted in durable objective responses in late-stage ovarian cancer patients typically not responsive to other immunotherapeutic agents. There is a gap in care for women with platinum sensitive ovarian cancer, who respond to chemotherapy but are ineligible for or cannot tolerate additional maintenance treatment. These patients have a less compromised immune system, providing the opportunity to harness the unique mechanism of action of COM701 to potentially change the disease trajectory improving progression free survival. Announcement • Oct 29
Compugen Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Compugen Ltd. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024 New Risk • Aug 15
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$9.5m Forecast net loss in 3 years: US$18m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 22% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). New Risk • Aug 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 23% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Breakeven Date Change • Aug 06
Forecast to breakeven in 2025 The 2 analysts covering Compugen expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 55% to 2024. The company is expected to make a profit of US$24.9m in 2025. Average annual earnings growth of 50% is required to achieve expected profit on schedule. Announcement • Aug 06
Compugen Ltd., Annual General Meeting, Sep 12, 2024 Compugen Ltd., Annual General Meeting, Sep 12, 2024. Location: co. offices, Israel Announcement • Jul 30
Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors Compugen Ltd. announced that the U.S. Food and Drug Administration has cleared the investigational new drug application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences Inc. (Gilead). The IND clearance triggered a $30 million milestone payment from Gilead and Compugen is on track to initiate the Phase 1 trial in solid tumors, in the fourth quarter of 2024. The Phase 1 trial is a first-in-human, dose escalation and dose expansion trial to assess the safety and tolerability of COM503 as a monotherapy and in combination with Gilead's anti-PD-1, zimberelimab in participants with advanced or metastatic solid tumors globally. In 2023, Compugen and Gilead entered into a license agreement, pursuant to which Gilead was granted exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including the COM503 drug candidate. Compugen is responsible for preclinical development and the anticipated first- in-human Phase 1 trial evaluating the safety and tolerability of COM503. Gilead will have the sole right to develop and commercialize COM503 thereafter. Gilead provided Compugen with a $60 million upfront payment and will make a $30 million payment for achievement of the milestone of IND clearance of COM503, the subject of this press release. Compugen will be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of up to $848 million. Compugen will also be eligible to receive single- digit to low double-digit tiered royalties on worldwide net sales. Announcement • Jul 23
Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024 Compugen Ltd. announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024 Announcement • May 16
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024 Compugen Ltd. announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. David has more than 15 years of experience working in finance, including 10 years of experience in the healthcare and biotech industries. Prior to joining Oramed Pharmaceuticals as Chief Financial Officer in 2021, David served as a Corporate Financial Planning and Analysis Director and as Global Internal Audit Senior Manager at Teva Pharmaceutical Industries Ltd. Earlier in his career, David provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management and served in the audit department of KPMG. David holds degrees in accounting and management from the French Ministry of Higher Education and Research and is a certified public accountant in Israel. Announcement • May 08
Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024 Compugen Ltd. announced that they will report Q1, 2024 results Pre-Market on May 20, 2024 New Risk • Mar 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$49m net loss in 3 years). Shareholders have been diluted in the past year (3.4% increase in shares outstanding). New Risk • Mar 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 21% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$49m net loss in 3 years). Buy Or Sell Opportunity • Mar 09
Now 20% undervalued Over the last 90 days, the stock has risen 188% to ₪8.77. The fair value is estimated to be ₪10.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 23% per annum. Earnings are forecast to decline by 21% per annum over the same time period. Announcement • Feb 21
Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024 Compugen Ltd. announced that they will report Q4, 2023 results Pre-Market on Mar 05, 2024 Announcement • Feb 15
Compugen Ltd. Announces Executive Changes Compugen Ltd. announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. Michelle joined Compugen in October 2023 as Vice President of Clinical Development. Most recently Michelle was the Chief Medical Officer of 1 E therapeutics Ltd., a drug development company, creating a novel class of programmable oligonucleotide therapeutics and Aummune Therapeutics Ltd., a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Michelle was Vice President of Clinical Development at C4 Therapeutics Inc., helping to build up the clinical development group and leading the successful submission of two INDs and initiation of Phase 1 studies. Prior to C4 Therapeutics, Michelle worked in R&D for 9 years at Janssen (now Johnson & Johnson). During her time there she gained experience in late-stage clinical development, pediatric development and global medical affairs while being a key member of the ibrutinib development team and held positions of increasing responsibility. In addition, Michelle supported key due diligence projects including the acquisition of Momenta Pharmaceuticals Inc., by Johnson & Johnson. Prior to starting in industry in 2011, Michelle trained at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell. She also spent time at Columbia Presbyterian and Mount Sinai Medical Center in New York. Michelle obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist. New Risk • Dec 21
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$60m net loss in 3 years). Market cap is less than US$100m (₪196.8m market cap, or US$51.0m). Announcement • Nov 05
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification Compugen Ltd. announced that on November 3, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). The receipt of the Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares from the Nasdaq Capital Market and has no current immediate effect on the listing or trading of the Company's ordinary shares on the Nasdaq Capital Market, under symbol ‘CGEN.’ Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until May 1, 2024, to regain compliance with the Minimum Bid Price Requirement. If at any time before May 1, 2024, the closing bid price of the Company's ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, unless Nasdaq exercises its discretion to extend this 10 day period pursuant to Rule 5810(c)(3)(H), the Company will be deemed to have regained compliance with the Minimum Bid Price Requirement, following which, Nasdaq will provide a written confirmation of compliance and the matter will be closed. In the event that the company does not regain compliance by May 1, 2024, the Company may be eligible for an additional 180 calendar day grace period provided that it meets the applicable standards for initial listing of its ordinary shares on the Nasdaq Capital Market (other than the Minimum Bid Price Requirement). To be eligible, the Company will also need to provide a written notice of its intention to cure the deficiency during this second compliance period by effecting a reverse share split, if necessary. If the Company does not regain compliance with the Minimum Bid Price Requirement during the second 180 calendar day grace period (by November 9, 2024), and is ineligible for an additional grace period, Nasdaq will provide written notice that the ordinary shares of the Company are subject to delisting from the Nasdaq Capital Market. In that event, the Company may appeal the determination to a Nasdaq hearings panel. The company intends to monitor the closing bid price of its ordinary shares. Receipt of the Nasdaq notification letter has no effect on the Company's business operations. Announcement • Nov 01
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer Compugen Ltd. announced it will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody in an oral presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place 3-5 November 2023, San Diego, CA. Key data that will be presented at SITC include: Antibody inhibition of IL-18BP prevented tumor growth across multiple mouse tumor models. Antibody induced inhibition of IL-18BP resulted in a significant increase in functional immune-cells such as the effector T-cells and induced a T cell clonal expansion in the tumor, as well as an immune memory response. Engineered IL-18 cytokine generated peripheral inflammatory responses evident by increased serum cytokines in contrast with an anti-IL-18BP antibody approach which modulated the tumor microenvironment without affecting the periphery. Oral presentation details: Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response. Abstract number: 550 Session: Cytokines in Cancer Date: November 3, 2023 Time: 3:30 PM - 5:10 PM PDT. The data will also be presented as a poster on November 4, 2023. Announcement • Oct 25
Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023 Compugen Ltd. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023 Board Change • Oct 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Member of Scientific Advisory Board Nils Lonberg was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Sep 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$61m net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (₪313.3m market cap, or US$82.1m). Announcement • Aug 08
Compugen Ltd., Annual General Meeting, Sep 20, 2023 Compugen Ltd., Annual General Meeting, Sep 20, 2023, at 17:00 Israel Standard Time. Location: 26 Harokmim Street, Bldg. D, Holon, Israel Holon Israel Agenda: To re-elect seven (7) directors to serve as members of the Board of Directors of the Company; to approve the Amended and Restated Compensation Policy of the Company; to approve compensation to the Company’s Chief Executive Officer; to approve an amendment to the Articles of Association of the Company; and to re-appoint Kost Forer Gabbay & Kasierer (a member of Ernst & Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023, and until the next annual general meeting of the Company’s shareholders and to authorize the Board, upon recommendation of the Audit Committee, to determine the remuneration of Kost Forer Gabbay & Kasierer (a member of Ernst & Young Global), in accordance with the volume and nature of its services. Announcement • Jul 25
Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023 Compugen Ltd. announced that they will report Q2, 2023 results Pre-Market on Aug 07, 2023 Announcement • Jun 23
Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study Compugen Ltd. announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer. Details on the study: This proof-of-concept study (NCT04354246) is an open label study evaluating the combination of COM701 with COM902 and pembrolizumab in up to 40 patients with high grade platinum resistant epithelial ovarian cancer including patients with fallopian tube cancer and primary peritoneal cancer who have received up to 3 lines of prior therapy for platinum resistant ovarian cancer. The study includes patients with all histologies. The initiation of the study is based on Phase 1 cohort expansion data reported at ESMO-IO 2022, showing a favorable safety and tolerability profile and durable anti-tumor activity with the combination of COM701 and nivolumab ± BMS-986207 in platinum resistant ovarian cancer patients. Announcement • Jun 14
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement Compugen Ltd. announced that on June 12, 2023, it received a notification letter (the ‘Notification Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (the ‘Nasdaq Capital Market Minimum Bid Price Requirement’). As announced on November 2, 2022, the company was notified that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the ‘Nasdaq Global Market Minimum Bid Price Requirement’). As announced on May 3, 2023, Nasdaq approved the Company's request to transfer the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, at which time Nasdaq granted the Company until October 30, 2023, to regain compliance with the Nasdaq Capital Market Minimum Bid Price Requirement for continued listing. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days. The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for the last 10 consecutive business days from May 26, 2023 to June 9, 2023 and that the Company has regained compliance with the Nasdaq Capital Market Minimum Bid Price Requirement. Announcement • Feb 14
Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023 Compugen Ltd. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 27, 2023 Announcement • Dec 07
Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer Compugen Ltd. announced publication of ePosters by ESMO Immuno-Oncology Congress 2022 (ESMO-IO), showing that Compugen's COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 (anti-TIGIT) demonstrated preliminary durable anti-tumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile. The Company plans to host an investor conference call and webcast tomorrow, December 7, 2022, at 8:30 AM ET to review this data and data from a small cohort of metastatic NSCLC patients treated with COM701 ± nivolumab planned to be presented at ESMO-IO, December 8, 2022, Geneva, Switzerland. ePosters are available on the ESMO-IO virtual platform, in the e-Poster section and the publication section of Compugen's website. Based on the data reported in the different studies, Compugen is planning to pursue two studies, with the purpose to strengthen the data it has already published and to build a path to future registration studies: The first, in up to 20 patients with metastatic MSS-CRC, immune checkpoint inhibitor naïve patients with = 2L of prior therapy, treated with a triple combination of Compugen's anti-PVRIG, COM701, and its own anti-TIGIT, COM902, and pembrolizumab. Enrolment is expected to be completed in 2023. The second is a follow up study currently under design in platinum resistant ovarian cancer immune checkpoint inhibitor naïve patients. Compugen expects to share initial findings by the end of 2023. Announcement • Nov 08
Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients Compugen Ltd. announced publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients. The data will be presented as an oral presentation by Michael Overman, M.D., University of Texas MD Anderson Cancer Center at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 10, 2022 in Boston, MA. Key findings from the abstract, “COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases” (NCT03667716), with a data cut-off date of June 17, 2022, include: COM701+ nivolumab combination is well tolerated with a favorable safety profile; ORR 2/22 (9%) higher than ORR (1-2%) reported for SOC- regorafenib or TAS-102; Encouraging preliminary antitumor activity in the subset of MSS-CRC patients with liver metastases, ORR 2/17 (12%), compared to 0% ORR historically for other immunotherapies in a U.S. patient population; and Translational data demonstrated potent TME immune activation, in the majority of patients based on 13 paired biopsies, most notable in responders and consistent with COM701 mechanism of action. Such modulation is not typical of checkpoint inhibitors in cold indications. Planned Next Steps: Further clinical investigation of COM701 and anti-PD-1, triple combination with COM902 in MSS-CRC patients and ESMO-IO presentation on December 8, 2022, of new encouraging clinical data from the fully enrolled dual and triple combination cohorts of COM701+nivolumab ± BMS-986207 in platinum resistant ovarian cancer patients. Announcement • Nov 03
Compugen Announces Receipt of Nasdaq Delisting Notice Compugen Ltd. announced that on October 31, 2022, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The receipt of the Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares and has no current immediate effect on the listing or trading of the Company's ordinary shares on the Nasdaq Global Market, under symbol "CGEN." Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until May 1, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before May 1, 2023, the closing bid of the Company's ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, the Company will be deemed to have regained compliance with the Minimum Bid Price Requirement, following which, Nasdaq will provide a written confirmation of compliance and the matter will be closed. In the event that Compugen does not regain compliance by May 1, 2023, the Company may transfer the listing and trading of its ordinary shares to The Nasdaq Capital Market, provided that it meets the applicable standards for initial listing of its ordinary shares on the Nasdaq Capital Market (other than the Minimum Bid Price Requirement) and may be eligible for an additional 180 calendar day grace period by providing a written notice of its intention to cure the deficiency during this second compliance period by effecting a reverse share split, if necessary. If the Company does not regain compliance with the Minimum Bid Price Requirement by May 1, 2023, and is ineligible for an additional grace period, Nasdaq will provide written notice that the ordinary shares are subject to delisting from the Nasdaq Global Market. In that event, the Company may appeal the determination to a Nasdaq hearings panel. Compugen intends to monitor the closing bid price of its ordinary shares. Receipt of the Nasdaq notification letter has no effect on the Company's business operations. Announcement • Nov 01
Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022 Compugen Ltd. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022 Announcement • Sep 13
Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer Compugen Ltd. announced that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team. Alberto will join Compugen on November 1, 2022. Alberto brings more than 30 years of industry experience to Compugen by serving in public and private companies. Throughout his career he has gained vast experience in leading financing, investor relations, M&A, and business development transactions. He most recently served as acting CFO at several startup companies in the high-tech industry. Prior to this, as CFO at Nasdaq and TASE listed Allot, he was instrumental in helping turn around the company to reach a path of sustained growth. Previously, Alberto spent seven years as Worldwide Group CFO at Nasdaq listed Amdocs with responsibility for the global financial business activities. Alberto holds a Master of Business Administration and bachelor's in economics and statistics from the Hebrew University of Jerusalem. Announcement • Jul 22
Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022 Compugen Ltd. announced that they will report Q2, 2022 results Pre-Market on Aug 04, 2022 Announcement • May 03
Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022 Compugen Ltd. announced that they will report Q1, 2022 results Pre-Market on May 16, 2022 Announcement • Feb 25
Compugen Ltd. Announces Board Changes Compugen Ltd. announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors effective March 1, 2022. In addition, the company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors. Announcement • Feb 11
Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022 Compugen Ltd. announced that they will report Q4, 2021 results Pre-Market on Feb 24, 2022 Announcement • Jan 19
Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies Compugen Ltd. announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer. U.S. Patent No. 11,225,523 titled "Triple Combination Antibody Therapies" augments previously issued patents by expanding and protecting the use of COM701 for treating cancer patients, to include the triplet combination of COM701 with any anti-PD-1 antibody and any anti-TIGIT antibody. U.S. Patent No. 11,225,523 is expected to expire no earlier than August 2037 in the United States. Announcement • Aug 20
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development Compugen Ltd. announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen's high affinity anti-TIGIT antibody, will advance into clinical development. AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. COM902 was licensed to AstraZeneca in 2018 exclusively for the development of bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities. Compugen retains all other rights to the program with exception to those licensed to AstraZeneca. Board Change • Jul 31
High number of new directors Independent Director Eran Perry was the last director to join the board, commencing their role in 2019. Announcement • Jul 20
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207 Compugen Ltd. announced that the first patient has been dosed in the cohort expansion arm of the Phase 1/2 study evaluating the triple combination of COM701, Compugen's first-in-class anti-PVRIG antibody, with Opdivo® (nivolumab) and Bristol Myers Squibb's investigational anti-TIGIT antibody, BMS-986207. Announcement • Jul 16
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies Compugen Ltd. announced that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination of COM902, the company's potential best-in-class, high-affinity anti-TIGIT antibody and COM701, Compugen's first-in-class anti-PVRIG antibody in patients with advanced malignancies who have exhausted all available standard therapies. The COM902 monotherapy dose escalation arm of this Phase 1 open-label study is complete. The Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of COM902 alone and in combination with COM701 in patients with advanced malignancies who have exhausted all available standard therapies. The COM902 monotherapy dose expansion study, will be in subjects with select tumor types, preferably multiple myeloma. The COM902 in combination with COM701 dose expansion arm is expected to be in select tumor types, PD1 refractory or relapsing HNSCC, NSCLC and CRC (MSS). The study is being conducted in multiple leading oncology clinical centers in the United States with an estimated enrolment of 90 participants across all arms. COM902 is a high affinity, fully human antibody that blocks the interaction of TIGIT with PVR, its ligand, and consequently enhances T cell function. Data suggests that COM902 has in vitro activity comparable or superior to TIGIT antibodies in clinical development. It is currently being evaluated in a Phase 1 clinical studies in patients with advanced malignancies who have exhausted all available standard therapies. Compugen has demonstrated in preclinical studies that simultaneous inhibition of TIGIT and PVRIG, the two coinhibitory arms of the DNAM axis, can increase antitumor immune responses, which may be further enhanced with the addition of PD-1 blockade. These data suggest that treatment with COM701 and COM902, targeting PVRIG and TIGIT, respectively, alone or in combination with a PD-1 inhibitor, has the potential to expand immuno-oncology treatment to patient populations who are non-responsive or refractory to existing immunotherapies. The discovery of TIGIT, using the company's computational discovery platform, was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS). COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2. Blockade of PVRIG by COM701 has demonstrated in preclinical studies potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. PVRIG and TIGIT, also discovered by Compugen's computational discovery platform in 2009, constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells. As such, preclinical data suggest that the inhibition of PVRIG together with TIGIT and/or PD-1 has the potential to further enhance anti-tumor immune response and improve patient outcomes in a broad variety of tumor types. Announcement • Jul 01
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study Compugen Ltd. announced that the first patient has been dosed in the combination expansion cohort of its ongoing Phase 1 clinical trial evaluating COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® (nivolumab). The indications for the combination therapy expansion cohort, ovarian, breast, endometrial and colorectal cancers were selected based on preclinical biomarker assessments. The Phase 1b combination cohort expansion study is part of the Phase 1 open-label clinical trial designed to assess the safety, tolerability and preliminary anti-tumor clinical activity of administering escalating doses of COM701 monotherapy, as well as in combination with Bristol-Myers Squibb's Opdivo® in patients with advanced solid tumors. The Phase 1b combination cohort expansion arm is currently recruiting patients in the United States. Announcement • Jun 30
Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis Compugen Ltd. announced the presentation of additional research supporting the differentiation of PVRIG from other immune checkpoint inhibitors. The latest findings suggests that PVRIG uniquely clusters with early memory/stem-like T cell gene markers indicating its potential as an important checkpoint involved in T-cell expansion. The totality of the data to date reinforces the hypothesis that PVRIG in combination with TIGIT and PD-1 inhibitors may be required to address tumors not responding to existing immunotherapy. The research will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Targets for Cancer Immunotherapy: A Deep Dive Seminar Series, as part of a seminar titled "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Target. Announcement • Jun 09
Compugen Ltd. Updates Data from Phase 1 Study of COM701 Compugen Ltd. updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). COM701 and Opdivo® combination arm dose escalation: In 15 evaluable patients, COM701 in combination with Opdivo® was well-tolerated with no reported dose-limiting toxicities up to the fifth and final dose cohort of COM701 20 mg/kg and Opdivo® 480 mg, both IV Fourth Quarter weeks. The disease control rate (DCR) was 66.7% (N=10) with best responses of complete response (CR) 6.7% (N=1), partial response (PR) 6.7% (N=1) and stable disease (SD) 53.3% (N=8). Previously reported patient with anal squamous cell carcinoma with confirmed CR remains on treatment at 96 weeks (22 months). This patient had three prior lines of therapy and enrolled within one month after progression on Opdivo® monotherapy. Previously reported patient with renal cell carcinoma with best response of SD remains on treatment at 75 weeks. A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported at AACR 2020 remained on study treatment for 44 weeks. COM701 monotherapy arm: Overall 36 patients enrolled. 16 patients, all comers in dose escalation and 20 patients in dose expansion; four patients of each: endometrial cancer, NSCLC, ovarian cancer, breast cancer and colorectal cancer (MSS). The disease control rate (DCR) was 47.2% (N=17) with best responses of partial response (PR) 2.7% (N=1) and stable disease (SD) 44.4% (N=16). Previously reported patient with primary peritoneal cancer (platinum resistant, MSS) with confirmed PR remains on study treatment at 79 weeks (18 months). Patient had three prior lines of standard-of-care treatment. Archival pre-treatment biopsy data revealed the patient was PD-L1 negative, with PVRL2 expression on tumor and endothelial cells, with an immune desert phenotype (i.e, no immune cells detected prior to treatment). Peripheral blood assessment showed immune activation as measured by immune cell proliferation and IFN? induction prior to tumor shrinkage. Demonstrated durable antitumor activity in extensively pretreated population: Durable responses to treatment (CR, PR or SD = 6 months) in 10/51 (19%) patients. Best responses of CR, PR, or SD were observed in 11/21 (52%) patients with prior treatment refractory disease. Best response of CR, PR or SD were observed in 13/18 (72%) patients with prior treatment with immune checkpoint inhibitors. Preliminary biomarker results demonstrate immune activation with COM701 treatment: Peripheral pharmacodynamic changes were measured via immune cell proliferation and cytokine levels in peripheral blood before and on treatment. After one treatment cycle, patients treated with COM701 monotherapy showed a trend of increased proliferation of effector memory CD8+ T cells (average change 87%), an immune cell population that expresses high level of PVRIG and are critical in driving anti-tumor immunity. Similar results were observed in the combination arm. Proliferation of NK-T cells, an immune cell population that expresses high level of PVRIG and plays a role in antitumor activity, increased significantly one day after COM701 monotherapy treatment, with a similar trend observed in the combination arm. Levels of IFN?, a cytokine which plays a key role in antitumor immunity, were upregulated following combination treatment of COM701 with Opdivo®, with a dose response trend with increasing doses of COM701, suggesting the observed activity is derived from the combination treatment and not Opdivo® alone. Anti-tumor activity was observed in PD-L1 low, PVRL2 positive patients, suggesting COM701 treatment may drive anti-tumor immunity even in patients with less inflamed tumor microenviroment. Announcement • Apr 29
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy Compugen Ltd. announced the publication of a peer-reviewed article titled "COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments Anti-Tumor T Cell Function in Combination with PVRIG or PD-1 Pathway Blockade" in Cancer Immunology, Immunotherapy. The preclinical data discussed in the paper highlight the potential of COM902, Compugen's anti-TIGIT therapeutic antibody, to enhance anti-tumor immune responses. Article highlights include: Development and characterization of COM902, a fully human anti-TIGIT antibody which binds specifically to TIGIT and disrupts the binding of TIGIT with PVR, the cognate ligand of TIGIT. Expression of TIGIT, a checkpoint within the DNAM-1 axis discovered in 2009 by Compugen and others, is induced on lymphocytes infiltrating the tumor microenvironment, including Tregs, effector T cells, and NK cells in diverse solid tumors. PVR is expressed in a large setof solid tumors. COM902, designed to have reduced Fc receptor engagement to avoid potential depletion of TIGIT-expressing effector T cells, does not demonstrate T cell depletion activity in-vitro or in-vivo, making it unlikely to elicit direct depletion of TIGIT-expressing effector T cells, which are important for anti-tumor activity. Blockade of TIGIT/PVR binding by COM902 enhances human T and NK cell function in vitro. This effect can be increased by dual blockade of COM902 with either an anti-PVRIG antibody, COM701, or an anti-PD-1 antibody. In vivo, in murine tumor models, COM902 combined with anti-PVRIG or anti-PD-L1 antibodies enhances anti-tumor lymphocyte responses and inhibits tumor growth. Analyst Estimate Surprise Post Earnings • Mar 01
Revenue in line with expectations Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 86% compared to a 34% growth forecast for the Life Sciences industry in Israel. Announcement • Feb 26
Compugen Ltd. Announces Data Update from Com701 Phase 1 Clinical Trial Compugen Ltd. reported updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by the company. Data highlights from the Phase 1 dose escalation studies as of the data cutoff of December 14, 2020 include: COM701 and Opdivo® combination dose escalation arm: In 15 patients with a median of five prior anticancer therapies (range of 2-10), COM701 in combination with Opdivo® was well-tolerated with no reported dose-limiting toxicities up to the fifth and final dose cohort of COM701 20 mg/kg and Opdivo® 480 mg, both IV Fourth Quarter weeks; The disease control rate (DCR) was 66.7% (N=10) with best responses of complete response (CR) 6.7% (N=1), partial response (PR) 6.7% (N=1) and stable disease (SD) 53.3% (N=8); A patient with anal squamous cell carcinoma with confirmed SD as reported at American Association for Cancer Research (AACR) 2020, now with confirmed CR and remains on treatment at 79 weeks. This patient progressed on Opdivo® prior to enrolling in the company's study; A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported at AACR 2020 remained on study treatment at 44 weeks; Durable responses of confirmed SD of six months or more in three patients. One patient with renal cell carcinoma remains on treatment at 58 weeks, and one patient with non-small cell lung cancer (NSCLC) (squamous) who failed prior treatment with immune checkpoint inhibitors remained on treatment at 36 weeks, and one patient with endometrial cancer remained on treatment at 46 weeks. COM701 monotherapy arm dose escalation update since AACR 2020: The patient with primary peritoneal cancer (platinum resistant, MSS) with durable confirmed partial response remains on study treatment at 62 weeks; The patient with pancreatic cancer, refractory to all three prior lines of standard of care (SOC) therapy with durable confirmed SD was on study treatment for 31 weeks. Data highlights from the monotherapy expansion cohort as of the data cutoff of December 14, 2020 include: 20 patients enrolled in biomarker and data informed indications; four patients of each: endometrial cancer, NSCLC, ovarian cancer, breast cancer and colorectal cancer; Six of the 20 patients (30%) had best responses of SD, one patient with endometrial cancer, three patients with NSCLC and two patients with ovarian cancer; Two patients with SD remain on treatment as of the data cutoff date; one patient with NSCLC who had >3 prior lines of SOC therapy; including prior treatment with immune checkpoint inhibitors with treatment ongoing at 26 weeks, and one patient with ovarian cancer with treatment ongoing at 20 weeks; Two additional patients remain on treatment as of the data cutoff date; No new safety findings were observed. Is New 90 Day High Low • Feb 23
New 90-day low: ₪33.90 The company is down 20% from its price of ₪42.12 on 25 November 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪34.08 per share. Announcement • Feb 17
Compugen Ltd. to Report Q4, 2020 Results on Feb 25, 2021 Compugen Ltd. announced that they will report Q4, 2020 results Pre-Market on Feb 25, 2021 Is New 90 Day High Low • Jan 29
New 90-day low: ₪38.90 The company is down 17% from its price of ₪46.66 on 29 October 2020. The Israeli market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 31% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪36.73 per share. Is New 90 Day High Low • Dec 29
New 90-day low: ₪39.28 The company is down 31% from its price of ₪56.73 on 30 September 2020. The Israeli market is up 26% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 07
New 90-day low: ₪41.40 The company is down 20% from its price of ₪51.74 on 08 September 2020. The Israeli market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 11
New 90-day low: ₪42.84 The company is down 29% from its price of ₪60.31 on 13 August 2020. The Israeli market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 26
New 90-day low: ₪47.47 The company is down 5.0% from its price of ₪49.84 on 28 July 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Oct 01
Compugen Ltd. Announces Board Changes Compugen Ltd. announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years of experience in the biopharmaceutical industry. Concurrently, Charles (Chuck) Drake, M.D., Ph.D. will be stepping down from Compugen'sSAB to pursue a new pharmaceutical industry role. Prof. Drake has served as a member of Compugen'sSAB since 2013. Dr. Nils Lonberg currently serves as Executive in Residence at Canaan Partners, an early-stage venture capital firm, having led drug discovery and platform development teams in the biopharmaceutical industry for the last 30 years. Prior to joining Canaan Partners, Dr. Lonberg spent 10 years with Bristol Myers Squibb, leading drug discovery efforts for immuno-oncology, most recently as Senior Vice President, Oncology Discovery Biology. Announcement • Jul 18
Compugen Ltd. to Report Q2, 2020 Results on Jul 30, 2020 Compugen Ltd. announced that they will report Q2, 2020 results at 9:00 AM, Israel Standard Time on Jul 30, 2020